Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 17/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068458 | 0.90 | ALDH1A1 (0.47) | NTRK1ABL1SIK1SIK2SIK3 | |
| SCHEMBL2065419 | 0.82 | NTRK1 (0.52) | NTRK1ITK | |
| SCHEMBL2066041 | 0.79 | NTRK1 (0.63) | NTRK1ITK | |
| SCHEMBL2066261 | 0.78 | KIT (0.62) | ABL1SIK1SIK2SIK3ITK | |
| SCHEMBL2065391 | 0.76 | NTRK1 (0.46) | NTRK1ITK | |
| SCHEMBL4254834 | 0.76 | LCK (0.52) | ABL1SIK1SIK2SIK3 | |
| SCHEMBL4254631 | 0.72 | ABL1 (0.50) | ABL1SIK1SIK2SIK3 | |
| SCHEMBL2065730 | 0.72 | MYC (0.39) | NTRK1ABL1SIK1SIK2SIK3 | |
| SCHEMBL20633817 | 0.71 | RAB9A (0.52) | ABL1SIK1SIK2SIK3 | |
| SCHEMBL12445981 | 0.71 | LCK (0.52) | ABL1SIK1SIK2SIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2099794-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079873-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | ERBB2, TEC, TTBK1 | NTRK1 327/4885ABL1 6/4885SIK1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.